# PDUFA dates March 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-03

> 46 FDA catalysts are dated in March 2027, including 8 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in March 2027?

PDUFA dates in March 2027: zanzalintinib (EXEL) on March 3, 2027; BRISTOL MYERS SQUIBB CO (BMY) on March 11, 2027; Anaphylm™ (dibutepinephrine, AQST) on March 16, 2027; ENFLONSIA (clesrovimab, MRK) on March 22, 2027; Valtoco (valtoco, AQST) on March 23, 2027; Eton Pharmaceuticals, Inc. (ETON) on March 29, 2027; and 2 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-03)

Source: Press release filed with the SEC (EX-99), accession 0000939767-26-000114, https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/fda-calendar/2027-03#answer

## PDUFA dates in March 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| March 3, 2027 | EXELIXIS, INC. | EXEL | zanzalintinib |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm) |
| March 11, 2027 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm) |
| March 16, 2027 | Aquestive Therapeutics, Inc. | AQST | Anaphylm™ (dibutepinephrine) | Type I allergic reactions | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm) |
| March 22, 2027 | Merck & Co., Inc. | MRK | ENFLONSIA (clesrovimab) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm) |
| March 23, 2027 | Aquestive Therapeutics, Inc. | AQST | Valtoco (valtoco) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm) |
| March 29, 2027 | Eton Pharmaceuticals, Inc. | ETON |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm) |
| March 29, 2027 | Aquestive Therapeutics, Inc. | AQST |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm) |
| March 31, 2027 | Atara Biotherapeutics, Inc. | ATRA | Tab-cel (tabelecleucel) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm) |

## All catalysts in March 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 2027 | [ARAKODA® (tafenoquine) primary completion](https://sec-api.dev/pdufa/tafenoquine) | SXTP | Babesiosis | scheduled | "NCT06207370 (Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor 60 Degrees Pharmaceuticals LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06207370)) |
| March 2027 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Obesity | scheduled | "NCT07011667 (A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011667)) |
| March 2027 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671001)) |
| March 3, 2027 | [Zanzalintinib PDUFA date](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab (Tecentriq®) for Previously Treated Metastatic CRC with Prescription Drug User Fee Act (PDUFA) Target Action Date of March 3, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm)) |
| March 2027 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT06524414 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524414)) |
| March 2027 | [MRNA-1647 primary completion](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | scheduled | "NCT05683457 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-06 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05683457)) |
| March 2027 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Asthma | scheduled | "NCT06977581 (A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977581)) |
| March 2027 | [Camlipixant primary completion](https://sec-api.dev/pdufa/camlipixant) | GSK | Irritable Bowel Syndrome | scheduled | "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07519395)) |
| March 2027 | [Menabcwy vaccine primary completion](https://sec-api.dev/pdufa/menabcwy-vaccine) | GSK | Meningitis, Meningococcal | scheduled | "NCT05087056 (Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-10 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05087056)) |
| March 11, 2027 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |
| March 2027 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Renal Cell Carcinoma | scheduled | "NCT03873402 (A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03873402)) |
| March 2027 | [FILSPARI (sparsentan) primary completion](https://sec-api.dev/pdufa/sparsentan) | TVTX | Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy | scheduled | "NCT05003986 (Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-12 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05003986)) |
| March 2027 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | scheduled | "NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-13 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760546)) |
| March 2027 | [Zl-1109 (vrdn-003) primary completion](https://sec-api.dev/pdufa/zl-1109-vrdn-003) | ZLAB | Thyroid Eye Disease (TED) | scheduled | "NCT07211776 (A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-14 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211776)) |
| March 16, 2027 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | scheduled | "Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm)) |
| March 16, 2027 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "the FDA's review of the Class 2 resubmission of the Anaphylm NDA and potential approval by the March 16, 2027 PDUFA goal date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/thirdquarter2026earnings.htm)) |
| March 2027 | [TAK-755 primary completion](https://sec-api.dev/pdufa/tak-755) | TAK | Thrombotic Thrombocytopenic Purpura (TTP) | scheduled | "NCT04683003 (A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04683003)) |
| March 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06480383 (Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06480383)) |
| March 2027 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK |  | scheduled | "NCT06517875 (Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517875)) |
| March 2027 | [Xeljanz (tofacitinib citrate) primary completion](https://sec-api.dev/pdufa/tofacitinib) | PFE | Ulcerative Colitis | scheduled | "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624230)) |
| March 22, 2027 | [ENFLONSIA (clesrovimab) PDUFA date](https://sec-api.dev/pdufa/clesrovimab) | MRK |  | scheduled | "In the U.S., the FDA set a PDUFA date of March 22, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm)) |
| March 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Neoplasm Malignant | scheduled | "NCT04976634 (Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04976634)) |
| March 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246916)) |
| March 23, 2027 | [Valtoco (valtoco) PDUFA date](https://sec-api.dev/pdufa/valtoco) | AQST |  | scheduled | "Final FDA approval for patients twelve years of age and older is subject to expiration of the orphan drug exclusivity for Valtoco® on January 10, 2027, and final FDA action, with a PDUFA goal date of March 23, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm)) |
| March 2027 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN |  | scheduled | "NCT04482309 (A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04482309)) |
| March 2027 | [EDI048 primary completion](https://sec-api.dev/pdufa/edi048) | NVS | Cryptosporidiosis | scheduled | "NCT07249463 (Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07249463)) |
| March 2027 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Fistulizing Crohns Disease; Perianal Crohns Disease | scheduled | "NCT05347095 (A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05347095)) |
| March 2027 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662319)) |
| March 2027 | [VX-993 primary completion](https://sec-api.dev/pdufa/vx-993) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06619860 (Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619860)) |
| March 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05639114 (Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639114)) |
| March 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Nonsegmental Vitiligo | scheduled | "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108283)) |
| March 29, 2027 | [Eton Pharmaceuticals, Inc. PDUFA date](https://sec-api.dev/companies/eton/catalysts) | ETON |  | scheduled | "An NDA with a March 29, 2027, PDUFA date is currently under FDA review and if approved, would add ages 6 to 11 to the product's label." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm)) |
| March 29, 2027 | [Aquestive Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | scheduled | "The Company has also submitted a Type 9 NDA seeking to add patients six to eleven years of age to the label, with a PDUFA goal date of March 29, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm)) |
| March 2027 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Radiographic Axial Spondyloarthritis | scheduled | "NCT07133633 (A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07133633)) |
| March 31, 2027 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | scheduled | "Tab-cel (tabelecleucel) is currently in Phase 3 development in the U.S. In September 2026, Pierre Fabre resubmitted the BLA for tab-cel, and in October 2026, the FDA accepted the resubmission for a Class 2 review with a target action date of March 31, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm)) |
| March 2027 | [Tisagenlecleucel primary completion](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma | scheduled | "NCT04094311 (Study of Out of Specification for Tisagenlecleucel): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04094311)) |
| March 2027 | [Posaconazole iv 6 mg/kg primary completion](https://sec-api.dev/pdufa/posaconazole-iv) | MRK | Invasive Fungal Infection | scheduled | "NCT04665037 (Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04665037)) |
| March 2027 | [Atm-avi primary completion](https://sec-api.dev/pdufa/atm-avi) | PFE | Gram-negative Bacterial Infections | scheduled | "NCT05639647 (Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639647)) |
| March 2027 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05648500 (A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648500)) |
| March 2027 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Vitiligo | scheduled | "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06163326)) |
| March 2027 | [Cretostimogene grenadenorepvec primary completion](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | High-Risk Non-Muscle-Invasive Bladder Cancer | scheduled | "NCT06567743 (Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567743)) |
| March 2027 | [Olverembatinib primary completion](https://sec-api.dev/pdufa/olverembatinib) | AAPG | GIST | scheduled | "NCT06640361 (A Study of Olverembatinib in SDH-deficient GIST.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06640361)) |
| March 2027 | [Ifx-hu2.0 primary completion](https://sec-api.dev/pdufa/ifx-hu2-0) | HURA | Advanced Or Metastatic Merkel Cell Carcinoma | scheduled | "NCT06947928 (Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor TuHURA Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947928)) |
| March 2027 | [SAT-3247 primary completion](https://sec-api.dev/pdufa/sat-3247) | MSLE | Duchenne Muscular Dystrophy; Duchenne; DMD | scheduled | "NCT07287189 (Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Satellos Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287189)) |
| March 2027 | [SNA02-48 primary completion](https://sec-api.dev/pdufa/sna02-48) | SVA | Tetanus | scheduled | "NCT07633119 (A Phase Ⅲ Clinical Study of SNA02-48 Injection): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Sinovac Life Sciences Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07633119)) |
| March 2027 | [Testosterone cypionate 75 mg primary completion](https://sec-api.dev/pdufa/testosterone-cypionate) | AMRX | Male Hypogonadism | scheduled | "NCT07898072 (Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Amneal Pharmaceuticals, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07898072)) |

Other months: https://sec-api.dev/fda-calendar/2027-02 , https://sec-api.dev/fda-calendar/2027-04. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates March 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-03

```bibtex
@misc{secapidev_fda_calendar_2027_03_20261116,
  title        = {PDUFA dates March 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-03}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_03_20261116","title":"PDUFA dates March 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-03","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
